Form 4: Supernus Pharmaceuticals Director Exercises Options and Sells Shares

Director Charles W. Newhall III exercised stock options and sold shares of Supernus Pharmaceuticals on November 11, 2024.

Summary

• On November 11, 2024, Charles W. Newhall III, a director of Supernus Pharmaceuticals, exercised stock options to acquire 20,000 shares of common stock at a price of $9.13 per share.
• Simultaneously, Newhall sold 10,700 shares of Supernus common stock at a weighted average price of $36.24, with individual sales ranging from $36.02 to $36.46.
• Following these transactions, Newhall directly owns 130,275 shares of Supernus common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the trading activities of company directors. It's a standard practice for publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading activities.
• Similar filings are made by directors and officers of companies like Amgen, Biogen, and Gilead Sciences when they trade their company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.

Key Dates